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Strengths and limitations of this study
 ► Comparable data on the chronic disease self- 
management programme implementation in five 
European countries with different backgrounds will 
be collected.
 ► The outcome of the used recruitment strategies, 
specifically designed for the vulnerable study popu-
lation, will lead to innovative conclusions.
 ► The study is not randomised controlled to allow all 
possible beneficiaries to participate.
 ► One of the limitations of the study is the fact that 
vulnerable people, who do not speak or understand 
the local language, cannot be included.
 ► Ideally, a longer- term trial should be conducted to 
measure the outcomes at 1 year postintervention.
AbStrACt
Introduction More than 70% of world mortality is due to 
chronic conditions. Furthermore, it has been proven that 
social determinants have an enormous impact on both 
health- related behaviour and on the received attention 
from healthcare services. These determinants cause 
health inequalities. The objective of this study is to reduce 
the burden of chronic diseases in five European regions, 
hereby focusing on vulnerable populations, and to increase 
the sustainability of health systems by implementing a 
chronic disease self- management programme (CDSMP).
Methods and analysis 2000 people with chronic 
conditions or informal caregivers belonging to vulnerable 
populations, will be enrolled in the CDSMP in Spain, 
Italy, the UK, France and the Netherlands. Inclusion of 
patients will be based on geographical, socioeconomic 
and clinical stratification processes. The programme 
will be evaluated in terms of self- efficacy, quality of life 
and cost- effectiveness using a combination of validated 
questionnaires at baseline and 6 months from baseline.
Ethics and dissemination This study will follow the 
directives of the Helsinki Declaration and will adhere to 
the European Union General Data Protection Regulation. 
The project’s activities, progress and outcomes will be 
disseminated via promotional materials, the use of mass 
media, online activities, presentations at events and 
scientific publications.
trial registration number ISRCTN70517103; Pre- results.
IntroduCtIon
In the 21st century, chronic conditions are 
among the most important public health 
challenges mainly due to their double impact: 
the human suffering they cause on the one 
hand and the damage they produce to global 
socioeconomic development on the other. 
Even though healthcare systems are still 
primarily focusing on acute diseases,1 they 
are slowly transforming because of demo-
graphic changes, the increasing prevalence of 
chronic diseases and the budgetary crisis of 
recent years. This shift requires new health-
care delivery models to ensure sustainability.
Chronic conditions and also vulnerable 
settings2 are part of the 10 threats to global 
health the WHO has warned of recently. More 
than 70% of mortality worldwide (41 million 
people each year), is due to chronic condi-
tions, such as cancer, diabetes, respiratory 
disorders and heart disease. All of them are 
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related to five main risk factors: tobacco consumption, 
physical inactivity, alcohol abuse, unhealthy diet and 
air pollution. Furthermore, 22% of the global popula-
tion lives in vulnerable settings which exist in almost all 
regions of the world. As a result, the 13th WHO General 
Programme of Work (2019–2023), expresses this concern 
with the slogan: ‘Promote health, keep the world safe, 
serve the vulnerable’, urging particularly to address 
health promotion in populations suffering vulnerability.3
The large impact of non- communicable diseases 
(NCDs) on national income is primarily due to loss 
of productivity caused by absenteeism and inability to 
work which threaten the sustainability of recent macro-
economic achievements. Additionally, there has been 
a steady global increase in healthcare expenditure on 
NCDs over the years. According to a systematic review 
on healthcare spending and national income, cardiovas-
cular diseases account for 12% of healthcare expenditure 
in the European Union (EU) and diabetes- related costs 
were estimated at 7%.4 Besides, other conditions and risks 
factors such as depression or obesity are becoming more 
prevalent in higher- income EU countries and are greatly 
determined by poverty and low income.5 6
Also, recent scientific evidence has shown the enor-
mous impact of social determinants (ie, income, unem-
ployment, housing quality, educational level or gender) 
on health, which manifest in diverse short- term and 
long- term health inequalities.7 These differences are not 
only related to deficient self- care behaviour1 and poor 
health but also to the insufficient attention from health-
care services. Vulnerable people are generally less likely 
to receive preventive care, timely diagnosis or follow- up 
care for their chronic conditions. These observations 
agree with the ‘inverse care law’ theory described in 
19718 by Tudor Hart, referring to the fact that often, the 
availability of good medical or social care varies inversely 
with the need of the population served. This way, chronic 
conditions and deprivation create a vicious circle.
Fortunately, there is evidence that chronic conditions 
can be controlled by reducing their risk factors,9 which 
are mostly linked to unhealthy lifestyle. There is also 
proof that health literacy programmes that focus on self- 
efficacy and empowerment can successfully modify many 
harmful habits.10 11
The basis of the EFFICHRONIC project is the interna-
tionally acknowledged chronic care model12 which aims 
to promote patients’ empowerment and autonomy. The 
specific programme used in the project is the chronic 
disease self- management programme (CDSMP).13 It 
concerns a process- centred intervention constructed 
on the social learning theory14 and it is appropriate 
for adults living with one or more chronic conditions. 
Since its beginning in 1990,15 the effectiveness of the 
CDSMP has been demonstrated through positive health 
outcomes and more efficient use of health resources.16 
The programme is community- focused and disseminated 
through an international infrastructure of training, certi-
fication and licensing.
Study rationale
Up to date, prevention research still concentrates mainly 
on disease- specific interventions and few studies on partic-
ularly vulnerable populations are performed. Moreover, 
data on the efficiency and cost–benefit of prevention 
programmes are scarce, which reduces policy engage-
ment and likewise, it prevents health systems from being 
more sustainable and efficient.17 18
EFFICHRONIC aims to empower individuals from 
(socially) deprived communities to manage their chronic 
conditions, in an integrated and non- disease specific 
way. The overall objective of the project is to reduce the 
burden of chronic conditions and increase the sustain-
ability of health systems by implementing a CDSMP in 
socioeconomically vulnerable populations in five Euro-
pean regions.
Five specific objectives have been defined: (1) to iden-
tify vulnerable people by means of a multidimensional 
analysis in the involved regions; (2) to design specific 
recruitment strategies to reach the target population; (3) 
to implement the programme in the five regions with at 
least 400 individuals per region; (4) to generate a compre-
hensive impact assessment framework, including cost- 
efficiency and health- economic assessment; and (5) to 
define guidelines and policy recommendations to allow 
to the scaling up of the EFFICHRONIC methodology to 
other regions in Europe.
MEthodS And AnAlySIS
Methodology
The methodology used for the community- based inter-
vention of EFFICHRONIC is the ‘chronic disease 
self- management programme’ developed at Stanford 
University. The CDSMP is a public health intervention 
provided by trained monitors. The programme is strongly 
evidence- based and consists of the following conceptual 
elements: self- efficacy, empowerment, salutogenesis, 
peer- to- peer education and vicarious training. It includes 
action planning and feedback about problem- solving 
skills and other competencies such as the reinterpreta-
tion of symptoms and training in disease management.
A cascade training model is used in the CDSMP method. 
On top are Self- Management Resource Centre licensed 
T- trainers possessing the maximum teaching expertise. 
They are in charge of training master trainers, who in 
their turn train monitors (or leaders) who will conduct 
the chronic disease self- management workshops. The 
monitors receive practical training on the philosophical 
and methodological basis of the CDSMP: empowerment, 
self- efficacy, group management, management of painful 
emotions, positive health and efficient communication 
among other skills. Once trained, the monitors facilitate 
the workshops in pairs. In each country, minimum 32 
monitors will be trained to instruct the end- users: people 
with chronic conditions or caregivers. The CDSMP work-
shops last for 6 weeks with sessions of 2.5 hours once a 
week in groups of 12–20 participants. The programme 
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Figure 1 EFFICHRONIC: inclusion criteria flowchart. MPI, 
Multidimensional Prognostic Index; NGO, non- governmental 
organisations.
fidelity and quality plan includes the supervision of work-
shops in the community by the master trainers through 
periodic protocolled monitor audits. Workshop assistants 
receive a handout with the workshop topics and home-
work assignments, a consultation book and a certificate 
of attendance if they were present at minimum 4 of the 
6 sessions.
Study design
EFFICHRONIC is a multicentre non- controlled prospec-
tive study with a duration of 3 years in five European 
settings: the Principality of Asturias in Spain, the area of 
Genoa in Italy, several regions in the UK, the Occitanic 
region in France and the area of Rotterdam in the Nether-
lands. The participating countries represent a wide range 
of social, economic and healthcare- related realities. The 
EFFICHRONIC intervention consists of the following 
phases: identification, recruitment and stratification of 
participants from vulnerable populations, implementa-
tion of the intervention and an economic and efficiency 
evaluation with a pre–post design. Additionally, guidelines 
and policy recommendations will be developed based on 
the project conclusions, this to allow the scaling- up of the 
intervention to other contexts.
Study population
The final study population will consist of 2000 vulnerable 
participants distributed over the five implicated areas, 
who finish the CDSMP (4 out of 6 sessions) and who are 
evaluated 6 months after the intervention. Taking into 
account a drop- out rate of minimum 20%, at least 2500 
participants will be recruited initially.
The vulnerability concept of EFFICHRONIC is based 
on a definition from the Spanish Red Cross which 
describes it as ‘a situation between complete social inclu-
sion and total exclusion’.19 Keeping in mind this defini-
tion and adapting it to some specific requirements of the 
CDSMP (eg, being able to understand the local language) 
and of EFFICHRONIC (being traceable for follow- up at 
6 months), the inclusion criteria were defined (figure 1).
The target population involves two main groups: vulner-
able people with at least one chronic condition, and 
informal caregivers who are socially isolated. In general, 
participants must be minimum 18 years old, reside in 
the selected geographical areas, have their basic housing 
needs met and possess adequate knowledge of the local 
language.
Participants with chronic conditions are either people 
older than 65 living alone or in a nursing home; people 
having difficulties to make ends meet (especially if 
belonging to an ethnic minority or being a legal immi-
grant, asylum seeker or refugee); or people who are 
imprisoned. A chronic disease, self- reported or clinically 
evaluated, is outlined as a pathology listed in the Interna-
tional Classification of Primary Care (ICPC-2) with a code 
between 70 and 99 in 1 of the 17 chapters and should 
have >6 months of evolution.
Informal caregivers are defined as people looking 
after a sick person, usually a relative, without receiving 
payment. Additionally, to be included in the study, it is 
required that they are socially isolated, as is the case of 
carers living in remote areas without transportation or 
with limited access to it (without a private car and public 
transport at >1 km from the house), without internet 
access or little social support.
General exclusion criteria are: going through a period 
of crisis (eg, being evicted), having severe mental health 
problems that cause a distorted perception of reality 
and/or inability to participate in group dynamics, having 
cognitive decline (eg, Alzheimer’s) or having active 
addictive disorders. Although the excluded groups are 
among the most vulnerable of society, they need other 
and more specific interventions before being eligible for 
a self- management programme.
Sample size
The study primarily wishes to demonstrate a statistically 
significant difference in the two subscales of the 12 items 
Short Form (SF-12)20 measuring health- related quality 
of life, and in the five participating countries. Based 
on a study on the effect of the CDSMP in lumbar back 
pain, the subscores ‘well- being’ and ‘energy’ of the SF-36 
improved by 6.0±19.1 and 4.3±23.2, respectively, after 
6 months.21 The lowest Cohen’s d is therefore of 0.185 in 
quality of life domains. Thus, the principal conclusion of 
the study will rely on 10 tests. Applying the Bonferroni’s 
correction on the significance threshold, we will consider 
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an alpha risk of 0.005 for the tests measuring the quality 
of life (self- rated with SF-12) in vulnerable patients with 
chronic diseases and caregivers. To show a statistically 
significant effect size of 0.185, by a paired Student’s t- test, 
with a bilateral alpha risk of 0.005, a power of 0.9 and a 
correlation between baseline and 6 months of 0, we need 
to analyse 978 subjects. Assuming a drop- out rate of 20%, 
we need to include at least 1223 subjects. The multicentre 
study will include 2000 subjects (400 per country), which 
will bring about sufficient power to analyse the objectives.
Sample selection and recruitment
The potential participants are being identified by means 
of geographical, socioeconomic and clinical stratification 
processes. A distinction is made between the individual 
and social dimension of vulnerability, leading to different 
recruitment strategies that will be combined to be more 
efficient. First, geographical mapping of areas with a 
higher percentage of vulnerable population was done 
based on existing national and local indices in all partic-
ipating countries. Consecutively, individualised recruit-
ment will take place in these areas employing specifically 
designed actions. Multiple recruitment channels are used 
in coordination with local agents from the healthcare 
system, social services and community- based structures. 
More specifically, the following profiles and organisations 
are involved in recruitment: health professionals, phar-
macists, social workers, non- governmental organisations, 
city councils and associations. The recruitment strategy 
at each study site is adapted to the specific local circum-
stances and collaborating organisations.
Stratification
To identify the people who will benefit most from the 
programme, individual socioeconomic and clinical 
parameters will be measured by a multidimensional 
stratification analysis. The tool used for this purpose, 
the ‘SELFY- MPI’, has been developed based on the vali-
dated Multidimensional Prognostic Index.22 The new 
tool is self- administrable and was specifically designed for 
EFFICHRONIC,23 adapting it to the broad adult popu-
lation (not limited to the elderly) and incorporating 
the socioeconomic parameters from the Spanish Gijón 
scale: education, income, cohabitation, age and social 
support.24 Income categories are country- specific and 
built on the corresponding minimum wages.
Implementation
Once the target population is identified and recruitment 
is ongoing, the programme can be implemented. To 
reach the target sample size of 2000 people, between 100 
and 140 workshops (20–28 per country) will have to be 
conducted. In practice, for about a year and a half, one 
workshop will start every month at each study site.
Evaluation
The last phase of the project consists of evaluating the 
effectiveness of the programme when it comes to changing 
health- related behaviour, self- efficacy and quality of life. 
Furthermore, the economic and efficiency impact will be 
analysed through cost–benefit analyses. An autoadminis-
trable impact questionnaire, containing validated scales 
and measuring tools, has been designed to assess these 
different outcome measures at baseline (T0, before the 
CDSMP) and 6 months (T1).25
Statistical analysis plan
Differences between baseline and follow- up measure-
ments will be assessed employing the paired T- test (for 
normally distributed variables), the Mann- Whitney U test 
(for variables not normally distributed) and the Pearson 
χ2 test (for variable fractions). To adjust for multiple 
testing, one- way analyses of variance with post hoc testing 
(type Bonferroni) will be performed. The relationship of 
an outcome measure (T1) with explanatory variables will 
be determined using ordinary least squares regression 
analysis. The outcome measure (T0), (change in) other 
outcome measures, risk factors and social determinants 
may serve as explanatory variables. Additionally, the above- 
mentioned analyses will be repeated for each country 
separately and possibly for other subgroups (for variables 
which are likely to influence the effect of the intervention 
itself, eg, age and gender). All data from each of the five 
pilot sites will be anonymised and centralised at one study 
site for statistical analysis. Analyses will be performed with 
SPSS V.25.0.
Guidelines and policy recommendations
By the end of the project, guidelines and policy recom-
mendations will be formulated based on the specific 
results of the participating countries. These recommenda-
tions will take into account acknowledged best practices 
at European level, to allow the scaling up of community- 
based interventions in vulnerable populations.
Patient and public involvement
Patients were not involved in the design of the study, 
choice of outcome measures or definition of the recruit-
ment strategies. However, some patients and caregivers 
take an active part in the conduct of the study as trained 
monitors, facilitating workshop sessions in the community. 
Study participants will be able to access the study results 
on request as stated in the participant information letter. 
News on the study progress is being published via various 
general and specialised media channels throughout the 
running of the study.
EthICS And dISSEMInAtIon
It is not considered ethical to conduct descriptive 
research on vulnerable subjects without running specific 
interventions afterwards. For this reason, the study is 
not randomised- controlled, being consistent with the 
principle of social justice and the ethics of working with 
marginalised groups.26
The study follows the directives of the Helsinki decla-
ration and the corresponding ethical regulations are 
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being respected at each study site. In Occitanie, France, 
the Ethics Committee of the South- west and Oversees 
I in Toulouse (Comité de Protection des Personnes 
Sud- Ouest et Outre- Mer I) approved the study on 05 
November 2018; study number 9788. In Genoa, Italy, 
the Regional Ethics Committee of Liguria (Il Comitato 
Etico della Regione Liguria) approved the study on 27 
March 2018; study number 152–2018. In Rotterdam, 
the Netherlands, the Medical Ethics Review Committee 
(Medische Ethische Toetsings Commissie; METC) of 
the Erasmus MC University Medical Center—Rotterdam 
approved the study on 23 November 2017; study number 
MEC-2017–1116.
In Asturias, Spain, the Research Ethics Committee of 
the Principality of Asturias (Comité de Ética de la Inves-
tigación del Principado de Asturias) approved the study 
on 31 January 2017; study number 20/17. In the UK, 
the online decision tool and query line of the Health 
Research Authority were consulted and it was concluded 
that approval from the NHS Research Ethics Committee 
was not necessary.
Eligible participants will be informed of the objectives 
and the procedures of the CDSMP in person by the inves-
tigator and in writing by a participant information letter 
before enrolment. Only after a sufficient period of reflec-
tion and after clarification of all questions, the participant 
will be asked to sign two copies of the informed consent 
form. Participation in the study is completely voluntary 
and participants have the right to withdraw their consent 
from the study at any time for any reason.
Data processing, communication and transfer are done 
following the EU Regulation 2016/679 of the European 
Parliament and of the Council of 27 April 2016, also 
known as the General Data Protection Regulation.27 Only 
the research team that has to maintain confidentiality has 
access to all collected study data. Only impersonalised 
information may be transmitted to third parties. Informa-
tion transmission to other countries will be carried out 
anonymously with a data protection level according to 
the mentioned regulation. The data will be collected and 
preserved in a codified way until the study is finished. The 
person responsible for data custody is responsible for the 
data file and treatment. At the end of the study, the data 
will be anonymised.
Via promotional materials, use of mass media, online 
activities, presentations at events and scientific publica-
tions, the project’s activities, progress and outcomes will 
be disseminated as described in a specific communication 
and dissemination plan. The strategy aims to enhance the 
engagement of healthcare and social care providers, civil 
society and public administration officers, all of which 
multipliers on account of their broad network and poten-
tial influence on the target population. Nevertheless, the 
main intended beneficiaries of the strategy are vulnerable 
people with long- term conditions and the health services 
serving these people. Accessing the hard- to- reach is one 
of the major challenges in EFFICHRONIC for which a 
solid strategy will be used.
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